Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
